An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

NCT02657343 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Ribociclib
DRUG: T-DM1
DRUG: Trastuzumab
DRUG: Fulvestrant

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]